Increased Binding of Beta-2-Microglobulin to Blood Cells in Dialysis Patients Treated with High-Flux Dialyzers Compared with Low-Flux Membranes Contributed to Reduced Beta-2-Microglobulin Concentrations

Abstract

Background: Patients on long-term dialysis eventually develop amyloid deposits with β₂-microglobulin as a predominant component. Although several studies have suggested that high-flux membranes reduce β₂-microglobulin in plasma compared with low-flux dialyzers, the mechanisms underlying this observation are still discussed. Methods: We revisited this important subject and measured β₂-microglobulin in the plasma of healthy individuals (n = 8), and patients undergoing hemodialysis (n = 20) who for assigned periods of time were either treated with a low-flux membrane (cuprophan) or high-flux (polyamide) dialyzer with an ELISA. The number of blood cells was determined by FACS. β₂-Microglobulin was also measured on the surface of granulocytes, lymphocytes, and monocytes before, directly after, and 4 h after hemodialysis. Expression of β₂-microglobulin, c-fos, tumor necrosis factor-α (TNF-α), and interleukin-1 mRNA was determined in whole blood samples with quantitative RT-PCR using an internal standard in parallel. In the second part of the study, patients were assigned in a two-group cross-over design either to low- or high-flux dialyzers (n = 9 in each group), and dialyzer membranes were changed every 4 weeks for two consecutive periods. Serum β₂-microglobulin concentrations were measured at the end of each period. Results: Healthy controls had a low plasma β₂-microglobulin level of 1.2 ± 0.3 mg/l. Before hemodialysis, patients on low-flux dialyzers had a plasma β₂-microglobulin level of 42.0 ± 14.0 mg/l, patients treated with high-flux dialyzers 21.5 ± 10.8 mg/l (p < 0.05 vs. low-flux dialyzers). In contrast, there was no significant difference in plasma concentrations of active transforming growth factor-β1 with the two different membrane types. The difference in serum β₂-microglobulin between low- and high-flux membranes was more prominent directly after hemodialysis as well as 4 h after hemodialysis compared with the values directly before the start of treatment. At all studied time-points, leukocytes and platelets were significantly higher in patients on low-flux membranes. Healthy control persons exhibited a significantly higher amount of β₂-microglobulin bound to granulocytes, lymphocytes, and monocytes compared with dialysis patients. Interestingly, β₂-microglobulin bound to granulocytes, lymphocytes, and monocytes was significantly increased in patients treated with high-flux membranes compared with low-flux filters. Quantitative RT-PCR revealed no significant difference in β₂-microglobulin expression in whole blood before hemodialysis, directly after hemodialysis, and 4 h after hemodialysis. However, TNF-α and c-fos transcripts were significantly higher in whole blood obtained from patients treated with low-flux membranes compared to high-flux dialyzers. The two-group cross-over study over three periods of 4 weeks revealed that switching from low-flux to high-flux dialyzers si...

Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease

“…Increased B2M binding to the surface of blood cells including granulocytes, lymphocytes and monocytes is characteristic of chronic hemodialysis, and co-occurs with vascular and renal amyloid deposits of this protein [59]. Notably, none of the patients involved in this analysis had end-stage renal disease or required dialysis.…”

Strategy for Degradomic-Peptidomic Analysis of Human Blood Plasma

“…β2-M-Fe were speculated to be responsible for the serial peaks based on different types of information including the mass shift of 52.9 Da that agrees with that of Fe 3+ →H 3+ , the reduced MS/MS spectrum quality that would result from the formation of the complex, and the co-existence of Fe with β2-M (29). β2-M has been found to be correlated to the clinical course of disease (30) and involved in cancer (31), however, the relevance of the β2-M different forms remains to be explored.…”

Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases

“…To the extent that this model is true, it would provide a partial molecular explanation for the clinical associations between higher β 2 M concentrations (greater disruption of β 2 M binding) and infectious mortality (210, 224, 225). This model yields hypotheses about the binding behavior of β 2 M to its targets, and the resultant regulation of biological processes, e.g., IFN-γ and immunoglobulin levels in relation to higher clearance (renal or dialytic), which can tested in small randomized crossover studies and laboratory experiments (218, 313, 329, 330). In that regard, a “candidate toxin” approach based on the EUToX Uremic Solutes Database (331) could provide a way to test a number of known toxins in vitro experiments for a disruptive effect on the protein complexes of β 2 M. Given the potent effect of inflammatory stimuli on the function of the MHC/β 2 M system, future work in this area should attempt to control for the confounding effects of microinflammation, which is prevalent in dialysis patients, as well as possible dialysis membrane–immune system interactions.…”